Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics (AKBA) plans to release its third-quarter 2026 financial results on November 5, 2026, before financial markets open.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Akebia Therapeutics (AKBA) plans to release its third-quarter 2026 financial results on November 5, 2026, before financial markets open. The results cover the quarter ended September 30, 2026. A conference call at 8:00 a.m. EST that day will discuss the results and recent business highlights. A live webcast and an archive will be available through the Investors section of Akebia’s website.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Akebia to Host Conference Call on Thursday, November 5 at 8:00 a.m. EST
WALTHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2026, on Thursday, November 5, 2026, prior to the open of financial markets.
Akebia will host a conference call on Thursday, November 5 at 8:00 a.m. EST to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial-in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time.
A live webcast of the conference call will be available via the Investors section of Akebia’s website at: https://ir.akebia.com/. An online archive of the webcast can be accessed via the Investors section of Akebia’s website at http://ir.akebia.com.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Waltham, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
